SCHEDULE 13G/A: BlackRock Discloses 4.9% Stake in LENZ THERAPEUTICS

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 4.9% of LENZ THERAPEUTICS, INC.'s common stock as of December 31, 2025.

Summary

• BlackRock, Inc. beneficially owns 1,537,723 shares of LENZ THERAPEUTICS, INC. common stock.
• This ownership represents 4.9% of the total outstanding common stock.
• BlackRock holds sole voting power over 1,510,589 shares and sole dispositive power over 1,537,723 shares.
• The shares were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of LENZ THERAPEUTICS, INC.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine disclosure of an institutional stake, which is generally a neutral event. The presence of a major asset manager like BlackRock as a significant shareholder can be seen as a minor positive signal of institutional confidence, but it's not a new investment decision or a change in strategy.

Positives

• BlackRock, a major institutional investor, holds a significant stake in LENZ THERAPEUTICS, INC., indicating potential confidence in the company.

Future Outlook

NA

Industry Context

This filing indicates continued institutional interest in LENZ THERAPEUTICS. BlackRock's position as a major asset manager means its holdings are often reflective of broader market trends or specific investment theses within the biotechnology or pharmaceutical sector, particularly for companies like LENZ focused on therapeutics.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence investor perception and liquidity.

Key Dates

Recommendation

This Schedule 13G filing is a routine disclosure of BlackRock's passive ownership stake in LENZ THERAPEUTICS, INC. at 4.9%. It does not indicate any intent to influence control or suggest new strategic developments for the company. While the presence of a major institutional investor like BlackRock can be a positive signal, this filing alone does not provide new information to warrant a change in investment thesis. Investors should continue to hold based on the company's fundamentals and other operational news.

Keywords

LENZ THERAPEUTICS, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake